Mineralys’ shares got a more than 50% boost Monday morning as new data showed its hypertension drug reduced blood pressure in ...
Pheiron and Ribo are excited to announce that the first two strategic collaboration milestones have been successfully ...
Any company looking to work with a CDMO should begin by defining its own product’s development requirements. For example, a ...
Clinical Trials Arena on MSN5d
Merck KGaA’s lupus drug fails in SLE cohort of Phase II trialMerck’s lupus drug enpatoran has failed to meet the primary endpoint in a subgroup of patients, but the drug's development is ...
Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...
The investment of over $6 million will expand LGM Pharma’s Rosenberg, Texas manufacturing facility as part of its Phase I ...
The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...
After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...
Pharmaceutical Technology on MSN2d
Vivace closes $35m in Series D for cancer drug developmentVivace Therapeutics has closed $35m in a Series D financing round to support the clinical development of its cancer drug ...
For more information on the Phase 1b clinical trial, visit: https://clinicaltrials.gov/study/NCT06732180 ...
Takeda Pharmaceutical has a robust drug discovery pipeline to meet future clinical demand. Check out the upside and downside ...
Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that portfolio company PharmNovo received positive feedback regarding its most advanced drug candidate, PN6047, in a pre-IND meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback